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Accepted 23 April 2019The incretin effect, the ampliﬁcation of insulin secretion occurringwhen glucose is taken in orally as compared to
infused intravenously, is one of the factors that help the body to tolerate carbohydrate/glucose ingestion. These
include 1) amount and type of carbohydrates; 2) gastric emptying rate; 3) digestion and absorption of the carbo-
hydrates; 4) secretion and effect of the incretin hormones; 5) disposition of absorbed nutrients/glucose. The
incretin effect can also be viewed as the fraction of the ingested glucose load handled via gastrointestinal mech-
anisms (including the incretin effect); it is calculated by comparison of the amount of glucose required to copy, by
intravenous infusion, the oral load. Typically, for 75 g of oral glucose, about 25 g are required. Thismeans that the
GastroIntestinal Glucose Disposal (GIGD) is 66%. Both the GIGD and the incretin effect depend on the amount of
glucose ingested: for higher doses the GIGDmay amount to 80%, which shows that this effect is a major contrib-
utor to glucose tolerance. The mainmechanism behind it is stimulation of insulin secretion by a proportional se-
cretion of the insulinotropic hormones GIP and GLP-1. Recently it has become possible to estimate their
contributions in healthy humans using speciﬁc and potent receptor antagonists. Both hormones act to improve
glucose tolerance (i.e. the antagonists impair tolerance) and their effects are additive. GIP seems to be quantita-
tively the most important, particularly regarding insulin secretion, whereas the action of GLP-1 is mainly
displayed via inhibition of glucagon secretion.
© 2019 The Author. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction - Factors Regulating Glucose Tolerance
Strictly speaking, the incretin effect refers to the ampliﬁcation of
insulin secretion, which occurs when glucose is taken in orally as com-
pared to infused intravenously [1]. Normally, the insulin response is
augmented by a factor of 2–3 after oral intake. Physiologically, this
phenomenon is one of the ways whereby the organism copes with the
intake of a carbohydrate load. Thus, it is one of the important mecha-
nisms governing glucose tolerance. Glucose tolerance is usually deﬁned
as the plasma glucose proﬁle after intake of a certain amount of carbo-
hydrate (glucose) relative to what is seen in a group of unquestionably
healthy individuals given the same carbohydrate meal. Impaired glu-
cose tolerance therefore refers to concentrations exceeding normal
boundaries of the excursions. Until recently, these boundaries were es-
sential for a diagnosis of impaired glucose tolerance or type 2 diabetes,
whereas today emphasis is on the integrated glucose levels, as reﬂected
in the concentration of glycated haemoglobin, haemoglobin A1c. So
how is glucose tolerance normally regulated? Looking at impairments
in glucose metabolism, it is customary to analyse fasting glucose con-
centrations and postprandial glucose excursions separately, and this is
reasonable since the mechanisms involved are different [2]. Of course,
if fasting glucose concentrations are elevated, the postprandial glucoseThis is an open access article under tproﬁle, everything else being equal, will also be shifted upwards, so
that postprandial levels are also abnormal, while at the same time the
gastrointestinal mechanisms for handling oral carbohydrate loads may
be completely intact. An example could be patients with steatosis of
the liver, where hepatic insulin resistance and hyperglucagonemia
may explain fasting hyperglycemia, but have limited impact on post-
prandial events. Also in patients with type 2 diabetes, it is reasonable
to distinguish between the postprandial and the fasting glucose levels,
because the two are independently associated with cardiovascular
risk [3]; thus, in subjects with well-controlled diabetes, postprandial
glycemia contributes relatively more to HbA1c than fasting hyperglyce-
mia, whereas fasting glucose contributes relatively more in subjects
with dysregulated type 2 diabetes [4]. The incretin effect, the topic of
the present review, is obviously one of the important determinants of
the postprandial glucose excursions.
Systematically, the following factors are important for postprandial
glucose excursions [5]:
1. The load of carbohydrates
This seems self-evident, but is nevertheless an important factor in
the planning of diets for people with glucose intolerance. Only recently
has it become generally accepted that low carbohydrate diets have a
major beneﬁcial effect on the course and risk of complications inhe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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icantly improved haemoglobin A1c levels and reduced liver fat (and
thereby improved insulin sensitivity and increased insulin clearance)
[6,7]. A related issue is the glycemic index of the ingested carbohydrates
– the lower the glycemic index, the lower the postprandial glucose
levels, and again it is assumed that such reductions will reduce the car-
diovascular risk [7].
2. Gastric emptying rate
Once the meal is ingested, the next important factor is the gastric
emptying rate. Clearly, liquid meals are emptied at faster rates than
solid meals and with different kinetic patters (exponential patterns for
liquids and, after a lag phase, linear for solids), but on top of that the
emptying rate is strictly regulated by the meal composition to result in
a rather constant transfer of nutrients to small intestine, corresponding
to between 1 and 4 kcal/min [8]. The actual emptying process consists of
a brief opening of the pyloric sphincter associated with a strong propul-
sive contraction of the antrum, resulting in a rapid ejection a bolus of
gastric contents into the duodenum, where peristalsis activated by the
possibly acidic bolus secures further onward transportation tomore dis-
tal segments of the jejunum. In this way a rather large mucosal surface
of the upper small intestine is rapidly exposed to the nutrients. Effective
upper intestinal mechanisms are now activated which result in a feed-
back, involving both long vago-vagal reﬂexes, probably also short, intra-
mural reﬂexes, as well as endocrine mechanisms (cholecystokinin, se-
cretin, perhaps also GLP-1, somatostatin?), secreted in response to
both acidity, osmolarity and speciﬁc nutritional constituents (glucose,
proteins, lipids), which all powerfully dampen further emptying from
the stomach [5,9]. The result is an adjustment of nutrient transfer to
the small intestine that depends on the composition and caloric density
of the chyme delivered to the small intestine. In this way the emptying
of an energy-dense meal will be spread out in time, presumably with
the purpose of preventing untoward effects of rapid emptying (early
and late dumping) and excessive increases in postprandial nutrient
(e.g. glucose) concentrations in plasma.
3. Digestion and absorption
In the small intestine, digestion and absorption of the nutrients are the
next processes with an impact on the resulting plasma proﬁle. Normally,
neither carbohydrate digestion nor absorption are limiting factors, which
is illustrated by the rapid and extensive absorption of glucose in condi-
tions with accelerated gastric emptying (e. g. operations where pyloric
function has been distorted) where rapid increases to abnormally high
plasma levels may be seen [10]. For complex carbohydrates, the story is
of course more complicated. However, the absorption rate is of great im-
portance for the next-in-line regulator of glucose tolerance, the incretin
effect. This is because the secretion of the incretin hormones is dependent
on the absorption rate of the nutrients (glucose/amino acids) by the en-
docrine cells responsible for their secretion [11,12].
4. The incretin effect
The incretin effects now sets in with its actions on the endocrine
pancreas, and in particular insulin secretion [13]. The details of this
will be discussed below.
5. Disposition/deposition of nutrients
The next and ﬁnal, important step in glucose tolerance is the dispo-
sition of the nutrients/glucose. Themost important factor is of course in-
sulin, which switches the liver from a site of glucose production in thefasting state to a site where part of the absorbed glucose may be taken
up and stored as glycogen. Changes in glucagon secretion are also im-
portant for this change in the liver's metabolic function, with glucagon
secretion normally being inhibited by the increasing plasma levels of
glucose and some of the gastrointestinal hormones, in particular GLP-
1. Impaired braking of hepatic glucose production (which is already
elevated in T2DM) will clearly have untoward effects on glucose toler-
ance as discussed above. Most of the absorbed glucose, however, travels
further on to the peripheral tissues, where two mechanisms are partic-
ularly important for the rate of glucose disposal: the mass action of the
elevated glucose concentration (also sometimes referred to as glucose
effectiveness) [14,15] and insulin's effect on glucose uptake in muscles
and adipose tissue. Given the presence of glucose transporters in the tis-
sues, it is clear that increases in the plasma concentration of glucose re-
sults in increased transfer of glucose to the intracellular compartment
by facilitated diffusion. Insulin's effect on glucose transport involving
the insertions of additional glucose transporters (GLUT4) in the plasma
membranes of the fat and muscle cells will augment the diffusion even
further. The postabsorption details and a discussion of the mechanisms
of action of insulin receptor signaling are beyond the scope of this pre-
sentation, but clearly the intracellular fate of glucose may affect the
rate of transfer, being dictated by the gradients driving the diffusion;
thus removal of glucose from the relevant membrane areas (by phos-
phorylation) is essential for continued transport and, similarly, further
metabolism of glucose-6-phosphate is important to prevent substrate
inhibition of this process [16]. In the glucose tolerant individual, the
ﬁnal deposition of glucose comprises oxidation and/or storage as glyco-
gen. These processes can be greatly accelerated in healthy individuals
(suggesting surplus capacity) [17], but may be severely compromised
in T2DM and may therefore inﬂuence postprandial glucose levels.
2. The Incretin Effect
2.1. Deﬁnition and Calculation. Gastrointestinally Mediated Glucose
Disposal (GIGD)
Among all these factors, how important is the incretin effect? It is
easy to quantitate the effect in terms of insulin responses: this is simply
done by comparing the insulin responses (the areas under the curve of
the insulin responses, or the C-peptide responses, whereby differences
in hepatic extraction of insulin are avoided; or ultimately, insulin secre-
tion rates calculated by de-convolution of C-peptide responses) to an
oral glucose load and an intravenous load adjusted so as to give rise to
the same peripheral (arterial) glucose concentrations (isoglycemia)
[18]. In this situation, the beta cells experience the same arterial glucose
concentrations and the difference between the oral and the intravenous
response is due to these gastrointestinal factors, the incretin effect. From
this comparison, it can be calculated that the incretin affect may be re-
sponsible for up to 70% of the insulin response to oral glucose. But can
the incretin effect be converted into its importance for glucose toler-
ance? Does it follow that an impaired incretin response will be associ-
ated with a similarly impaired glucose tolerance? [19].This important
question has not until recently (see below) been properly addressed.
An alternative way of looking at the incretin effect is to measure the
amount of intravenous glucose required to copy the oral curve. For in-
stance, how much glucose does it take to copy, by infusion, the glucose
response to a 75 g oral load? It turns out to be around 20–25 g in young
healthy individuals. The difference is about 50 g. In otherwords, the oral
intake involves activation of mechanisms that enable the body to dis-
pose of 2/3 of the ingested load in addition to those activated by the in-
creases in plasma glucose alone [18]. This amount has sometimes been
referred to as GIGD, gastrointestinally mediated glucose disposal
[20,21], and GIGD amounts to 66% in this example. GIGD has by some
been called “the poor man's incretin estimate”, but actually the GIGD
is the physiologically relevant parameter, addressing the question:
how good is the body to mitigate the challenge of a large carbohydrate
Fig. 1. Plasma glucose responses in 6 young healthy subjects to ingestion of increasing amounts of glucose (25 g, 50 g 75 g) and intravenous infusions of glucose designed to copy the
plasma proﬁles after oral ingestion. The average amount of glucose required for the infusions is indicated in the top panel. Men +/− SEM. From Nauck et al. [18]with permission.
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and tissue uptake, etc. are details that we can deal with once we have
got an impression of how well the body handles the carbohydrate
load. In fact, GIGD can be calculated also in type 1 diabetic subjects
(where the incretin effect of course has no meaning), in whom it may
actually reach negative values! [22].
2.2. The Incretin Effect is Dose-dependent
So, is the incretin effect a constant ﬁgure? The amount of carbohy-
drate we ingest is highly variable, so perhaps it is not surprising that
the incretin effect is also variable. As mentioned, the effect may be esti-
mated from the amounts of intravenous glucose required to copy the
oral administration. In elegant experiments, Nauck et al. [18] looked at
the incretin effect after ingestion of 25, 50 and 100 g of glucose (in
equal volumes) (Fig. 1). The immediately most striking result was that
virtually identical plasma glucose concentrations resulted from these
ingestions, regardless of the dose administered. One can conclude thatFig. 2. Insulin and C-peptide responses from the experiments show in Fig. 1. Filled circles: ora
indicated signiﬁcant differences. From Nauck et al. [18] with permission.the body has a very effective mechanism that keeps the plasma glucose
concentrations low regardless of the amount of glucose we ingest. So
how much glucose was infused to copy these curves? About 20 g were
required for the 25 g dose and, as expected, about 20 g were required
after the other two oral doses as well. So the GIGD mechanism is sufﬁ-
cient to account for as much as 80% of the disposal of an oral glucose
load of 100 g! But what is the explanation? The explanation is apparent
by inspection of the insulin curves (Fig. 2), which show a progressive
andmassive increase in insulin secretion elicited in spite of the identical
plasma glucose concentrations [18].
2.3. The Incretin Hormones
The question then arises, which factors are responsible for this
excess stimulation. Here, the so-called incretin hormones, glucose-
dependent insulinotropic polypeptide (GIP) and glucagon-like
peptide-1 (GLP-1) are probably themost important [13]. These peptides
of the glucagon – secretin family of peptides are secreted froml glucose ingestion; open circles: intravenous glucose infusion. Mean +/− SEM. Asterisks
Table 1
Summary of the effects of GLP-1 and GIP: similarities and differences.
Effects GIP GLP-1
Beta cell proliferation/apoptosis inhibition ↑↑ ↑↑
Insulin secretion ↑↑↑ ↑↑↑
Insulin secretion in T2DM (↑) ↑↑
Glucagon secretion ↑↑ ↓↓↓
Somatostatin (pancreatic) secretion ↑↑ ↑↑
appetite → ↓↓
Food intake → ↓↓
Body weight → ↓↓
Efferent vagal activity → ↓↓
Gastric emptying → ↓↓a
Gastro-pancreatic secretion → ↓↓a
Mesenteric blood ﬂow ↑ →
Adipose tissue blood ﬂow ↑↑ →
Heart rate ↑ ↑↑
Adipocytes (lipolysis, lipid uptake)b ↑↑ →
Bone resorption ↓↓↓ ↓
Bone formation ↑ →
a Via inhibition of the efferent vagus.
b Lipolysis in the absence of insulin, net lipid uptake in the presence of insulin.
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glucose is a particularly powerful stimulus for both, and the secretion
of them also depends on the amount of glucose ingested (Table 1). In
experiments with increasing oral doses of glucose, plasma concentra-
tions of both GIP and GLP-1 were measured [23] (Fig. 3). It is clear
that the secretion of both is stimulated very rapidly, probably at the
ﬁrst emptying of gastric contents into the small intestine, and then con-
tinues at a rate which is proportional with the graded emptying of the
stomach contents. Thus, the duration of the response, not the ampli-
tude, depends on the total amount of glucose ingested in agreement
with the observation that the emptying rate is kept rather constant.
3. GIP and GLP-1
3.1. Secretion of GLP-1 and GIP
The incretin hormones are peptides of 42 and 30 amino acids,
respectively, and are secreted by open type endocrine cells of the
intestinal epithelium, the so-called K- and L-cells [24]. The density of
the K-cells is very high in the duodenum and proximal jejunum,
whereas the L–cells are more numerous more distally, and are even
found at high densities in the colon [25]. This immediately suggests
that they may have different roles, with GIP acting as an early incretin
and GLP-1 perhaps playing a greater role later. Nevertheless, secretion
of the two hormones generally shows up at the same, very early time
point [26], and experiments in rats have shown that the upper half of
the small intestine can produce GLP-1 with the same kinetics and in
similar amounts as the distal small intestine [27]. However, in a recent
human study [21] involving intestinal intubation, intraluminal infusions
of glucose in either themid duodenum or 177 cm further down showed
more GIP and less GLP-1 upon duodenal infusion, and more GLP-1 and
less GIP upon distal infusion, which would seem consistent with their
anatomical distribution. The two cell types are of the open type, mean-
ing that an apical process of the cells equipped with microvilli reaches
the intestinal lumen [28,29]. The luminal membranes are thought to
be equipped with SGLT-1 co-transporters allowing entry of glucose
into the cells [30]. The simultaneous entry of sodium ions is thought
to cause a depolarization of themembrane potential leading to opening
of calcium channels, and exocytosis of the contents of hormone-
containing granula from the basolateral side [30]. Thus, inhibition of
these voltage-gated calcium channels with nifedipine blocks the effect
of luminal glucose [31]. The important observation here is that secretion
is coupled to absorption which explains the relationship between the
glucose absorption proﬁles and hormone release [12].3.2. Incretin Receptors and Signaling
The two incretin hormones have speciﬁc receptors (a single type
for each) that are expressed in high numbers on the beta cells
explaining that elevated plasma concentrations may result in stimu-
lated insulin secretion [32,33]. Both receptors couple to a GαS pro-
tein mediating activation of adenylate cyclase and cAMP formation.
Activation of protein kinase A as well as the EPAC2-pathway is
responsible for further signaling leading to insulin granule exocyto-
sis [34,35]. Both hormones also activate transcription of genes
required for insulin production and for most other essential proteins
in beta cell function, and both hormones may exert trophic actions
on young beta cells, leading to proliferation [35,36]. The latter is of
course of major clinical interest, but the response seems to limited
to very young beta cells [37], very different from those of middle
aged or older patients with type 2 diabetes, in whom a proliferating
effect apparently has not been seem. Both hormones also seem to be
able to inhibit beta cell apoptosis, induced by both cytokines and
fatty acids [38], and with beta cell apoptosis apparently being a
major problem in T2DM [39], this may be equally clinically impor-
tant. In essence, both hormones potentiate glucose-induced insulin
secretion, meaning that they do not have any effect in the absence
of a glucose stimulus [40,41]. Although not completely worked out,
it is possible that they interact with KATP-channel activity in a PKA
dependent manner, facilitating inhibition of channel activity by
ATP generated in glucose metabolism [35]. Whatever the mecha-
nism, the result is that the peptides normally cannot cause
hypoglycaemia, because they lose effectiveness as glucose concen-
trations fall [42]. In support of this theory, it has been found that
the glucose dependency of GLP-1's effect on insulin secretion can
be uncoupled by sulfonylurea compounds acting to inhibit the
KATP channels [43]. This has clinical implications, by increasing the
risk of hypoglycaemia when GLP-1 receptor agonists are combined
with sulfonylureas. It has also been suggested [44] glutamate, de-
rived from the malate-aspartate shuttle upon glucose stimulation,
underlies the stimulatory effect of incretins and that glutamate up-
take into insulin granules mediated by cAMP/PKA signaling ampliﬁes
insulin release. This is of particular interest since glutamate produc-
tion is diminished in pancreatic islets of animal models of diabetes,
while a membrane-permeable glutamate precursor restored ampliﬁ-
cation of insulin secretion in these models [44]. Thus, cytosolic gluta-
mate may represent the elusive link between glucose metabolism
and cAMP action in incretin-induced insulin secretion.
3.3. Comparing GIP and GP-1
So are the two hormones completely equivalent? GLP-1 seems to be
more potent than GIP [45], but themajor difference lies in the effective-
ness of the two hormones in type 2 diabetes, where GLP-1 retains it
stimulatory activity, whereas that of GIP is almost completely lost
[46,47]. This phenomenon is currently unexplained. Down regulation
of GIP receptor in T2DMhas been proposed, supported by animals stud-
ies, where a down regulation was observed in experimental diabetes
[48,49]. In humans, this does not seem to explain the difference; there
is actually a small early insulin response to GIP during a hyperglycemic
clamp in patients with T2DM (of little consequence for glucose turn-
over),whereas the late phase response of insulin secretion is completely
lost [47]; in contrast, in the same individuals, GLP-1may restore insulin
secretion to the rates of non-diabetic controls, exposed to the same
clamp (but without GLP-1). However, the early phase response to
GLP-1 is also reduced in patients with T2DM, and if one compares the
patients' early responses to GIP and GLP-1 with those obtained in
healthy controls, their relative magnitude is exactly the same [47].
This must mean that the receptor expression is unchanged (or changed
similarly for GIP and GLP-1), and that post receptor events, therefore,
must explain the GIP failure.
Fig. 3. Paracetamol, glucose, GLP-1 and GIP concentrations in plasma in 8 healthy volunteers after oral ingestion of 25, 75 and 125 g of glucose as well as intravenous glucose infusions
designed to copy the proﬁles after oral ingestion. Mean +/− SEM. From Bagger et al. [23]with permission.
50 J.J. Holst / Metabolism Clinical and Experimental 96 (2019) 46–553.4. The Importance of Incretin Postsecretory Metabolism
The two hormones also exhibit another important difference. Fig. 2
shows the secretion proﬁles of the two hormones, but do these proﬁles
correspond to their impact on the beta cell? This turns out not to be
the case, and the difference lies in their postsecretory fate. Both are
secreted in an intact, fully active form: GLP-1 as an amidated peptide
of 30 amino acids [50], usually, for historical reasons, designated GLP-1
7–36 amide, GIP as a non-amidated 42-amino acid peptide. But both
peptides are substrates for the almost ubiquitous enzyme, dipeptidyl
peptidase 4, which is circulating, but also bound to cell membranes in
the liver, the kidneys and to the luminal surface of endothelial cells
[51]. The enzyme cleaves off the two N-terminal amino acids, leaving
behind truncated peptides, which have lost their insulinotropic proper-
ties and actually may act as, rather weak, receptor antagonists [52,53].
The DPP-4 mediated degradation leaves GIP with a half-life in the circu-
lation of 7 min [54], which can be determined with assays for the intact
peptide, either C-terminal radioimmunoassays, or even better, sandwich
ELISAs relying on antibodies against both of the intact termini of themol-
ecule. The metabolite has a half-life around 30 min consistent with an
elimination predominantly due to glomerular ﬁltration in the kidneys.
In humans, around half of circulating GIP is present in the intact form,
and this must be considered when plasma proﬁles obtained with assays
for total GIP (i. e. the intact hormone + the metabolite, which is what is
measuredwith assays directed at the C-terminus) are evaluated [55]. For
GLP-1, the degradation is even more extensive. GLP-1 is exquisitely
sensitive to DPP-4 and most of the newly secreted GLP-1 is broken
down already in the capillaries of the gut, so that only about 2/3 or 1/4
of what arrives to the liver remains intact [50]. In the liver, 50% of what
is presented is broken down so that in total about 12% of what was
secreted arrives to the systemic circulation in the intact form [56]. And,
because of the soluble DPP-4, it has been found that only about 8% of
what was released arrives at the peripheral targets (e. g. the endocrine
pancreas) in the intact form [57]. The half-life observed in infusion stud-
ies is around 1–2 min, but the plasma clearance is up to 3 times thecardiac output [58], indicating that there is no equilibrium and that the
peptide is continuously broken down at multiple sites in the circulation.
So, how can the hormone be effective under these circumstances? After
particularly largemeals, there is ameasurable increase in the concentra-
tion of the intact hormone, which is otherwise very low and most often
undetectable, and this increasemay of course inﬂuence beta cell function
[59]. However, numerous observations support that GLP-1 mainly acts
by activation of sensory vagal afferents expressing the GLP-1 receptor
[60] (Fig. 4). There is a dense network of nerve ﬁbres staining positively
for the GLP-1 receptor in the intestinal wall [61], andmany cell bodies in
the nodose ganglion (harbouring the cell bodies of the vagal afferents)
express GLP-1 receptor mRNA [62]. These sensory ﬁbres terminate in
the nucleus of the solitary tract (NTS) in the brain stem, and after periph-
eral administration of GLP-1, c-fos activation can be observed in a subset
of nuclei in the NTS [63]. Efferent vagal motor nuclei in the dorsal vagal
complex may also show signs of activation, suggesting that the efferent
vagus is also stimulated [64]. In other words, long vago-vagal reﬂexes
may transmit the signals generated by peripheral GLP-1, acting on
nerve ﬁbres in the gut wall and before it is taken up by capillaries and
getting degraded. From the NTS, projections may also reach the hypo-
thalamus, where activation (c-fos) has been observed in several nuclei
including the paraventricular nucleus [65]. The powerful inhibitory ac-
tions of GLP-1 on the motor and secretory activity of the organs of the
upper gastrointestinal tract are undoubtedly mainly transmitted via
this pathway, since these activities are completely dependent on intact
vagal nerve [66]. It is also possible that circulating GLP-1 may penetrate
into the brain via the leaks in the blood brain barrier; indeed, the GLP-1
receptor is expressed in the regions where these leaks are found, includ-
ing the area postrema, the median eminence, the arcuate nucleus and
the subfornical organ [67,68].Most likely, the therapeutic GLP-1 receptor
agonists use this pathway to exert their actions on appetite and food in-
take. For GIP, similar mechanisms of action are not known to exist, but
GIP may also access the brain via these leaks, and since there is expres-
sion of the GIP receptor in the brain [32], it cannot be excluded that
some of the actions of GIP also involve the central nervous system.
Fig. 4. Activation of long vago-vagal reﬂexes by GLP-1 before it gets degraded by dDPP-4 in the intestinal capillaries and the portal circulation. Schematic drawing of a villus with an L-cell
secreting GLP-1 in the intact form (black dots)whichmay interactwith GLP-1 receptors on sensory vagal afferents in the intestine (f), the portal vein (e), or the liver (d), originating in the
nodose ganglion (c) and projecting to the nucleus of the solitary tract (a) in the brain stem. Here activated neurons may signal to the dorsal vagal motor complex (b) or to the
hypothalamus. Activated efferent vagal neurons may signal to the stomach (g) and the pancreas (h). The percentages of GLP-1 surviving in the intact form are indicated. From Holst &
Deacon [94] with permission.
51J.J. Holst / Metabolism Clinical and Experimental 96 (2019) 46–553.5. The Physiological Roles of GIP and GLP-1: The Receptor Antagonists
What is the contribution of the two hormones to the overall incretin
effect andwhich hormone ismore important?Originally itwas thought,
based on infusion studies, that both hormones required elevated glu-
cose levels to be effective, and their relative efﬁcacy was debated on
the light of this. However, in careful studies [45], inwhich the hormones
were infused to reach precisely the concentrations observed in healthy
individuals duringmeal intake and involving clamping of glucose levels
at the fasting level and at levels corresponding to normal postprandial
levels (up to 7 mmol/L), it was shown that both hormones acted oninsulin secretion already at fasting glucose concentrations, and more
so as glucose levels were increased, and that the two hormones stimu-
lated insulin secretion about equally, GLP-1 a little bitmore at the higher
glucose concentrations. An important difference also emerged: one,
GLP-1, strongly inhibited glucagon secretion, beyond the suppression
caused by the glucose infusions, whereas the other, GIP, if anything,
stimulated glucagon secretion [45]. But these experiments do not really
tell us about the overall importance of the two hormones, and do not
allow us to distinguish between their contributions, although previous
studies of the exogenous hormones indicated that they would have
additive effects [69].
52 J.J. Holst / Metabolism Clinical and Experimental 96 (2019) 46–55For this, receptor antagonists are needed. For GLP-1, a receptor
antagonist has been known since Raufman and Eng identiﬁed
exendin-4 as a full agonist of the GLP-1 receptor and found that the
truncated form, exendin 9–39, is a potent antagonist of the receptor
[70]. The ﬁrst experiments in humans with the new receptor antagonist
were carried out a few years later [71,72]. The antagonist clearly led to
increased glucose levels, but in those experiments themost conspicuous
effect was increased levels of glucagon, conﬁrming the role of GLP-1 in
the control of glucagon secretion, although the effect in the fasting
state was a surprise, since it would imply an action on pancreatic gluca-
gon secretion of the basal, fasting levels of GLP-1, which are very low.
Further experiments carried out with the antagonists conﬁrmed the
actions on glucagon secretion, but in experiments involving duodenal
infusions of glucose, whereby the powerful actions of GLP-1 on gastric
emptying rates were circumvented, it was clear that GLP-1 also, as pre-
dicted, plays a role for post glucose insulin secretion [73,74]. Indeed, inFig. 5. Insulin, C-peptide and glucose responses from experiments in 17 healthy but overweigh
placebo infusion; during infusion of the GLP-1 receptor antagonist exendin [9–38]; during infus
antagonists. Panel C shows areas under the curves for C-peptide; Panel E: ratios between C-p
signiﬁcant differences. Mean +/− SEM. From Gasberg et al. [86].individuals with exaggerated GLP-1 secretion e.g. after gastric bypass
operations, exendin 9–39 eliminated all the beneﬁts of the operation
on insulin secretion [75]. However, a paradoxical increase in insulin se-
cretion has been seen in some individuals in most studies [71,72,76,77].
There is currently no clear explanation for this. It has been speculated
that the elevated glucose concentrations resulting from antagonist
infusion (a consequence of the elevated glucagon concentrations) may
explain the increase [71]; indeed, the increases in glucagon are consid-
erable andmight contribute – after all, glucagon is a rather potent stim-
ulant of insulin secretion. The effect on insulin secretion could be due to
both systemic effects of the arterial hyperglucagonemia or local para-
crine effects of the high concentrations of glucagon in the islets, which
might stimulate the beta cells directly (via their glucagon receptors)
[78]. In animal experiments, it was observed that blockade of one of
the incretin receptors might be associated with increases in the secre-
tion of the other [79]. This has not been conﬁrmed in human studies.t/obese subjects given an oral glucose tolerance test (75 g) at time 0 on 4 occasions: after
ion of the GIP receptor antagonist GIP (3−30)NH2; or during combined infusion of the two
eptide and glucose and panel F: AUC for these ratios. Asterisk in panels C and F indicate
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identiﬁed after systematic studies of various truncations of the GIP
molecule in the laboratory of Mette Rosenkilde at the University of Co-
penhagen, which conﬁrmed some receptor antagonistic properties of
the truncated forms of GIP, GIP 3–42 and also GIP 5–42 [80,81]. The
GIP molecule has a cleavage site for proteolytic endopeptidases (i.e. a
pair of basic amino acid residues) at positions 32 and 33, and an early
search for a truncated form of GIP corresponding to GIP 1–31 or 1-
30amide (assuming that the carboxyterminal Gly would function as
substrate for the amidating enzyme and donate the amino group to
the preceding residue no 30) revealed presence of GIP 1-30amide in
the alpha cells of the murine pancreas [82]. It was not possible to con-
ﬁrm this observation with sensitive assays for the GIP 1-30amide, but
small amountswere indeed found in extracts of the gut and low concen-
trations were found in the circulation (but not after pancreatectomy)
[83]. Given the sensitivity of this molecule towards DPP-4, it was
assumed that the truncated form GIP 3–30NH2 would also exist. This
form turned out to be a high potency antagonist on the human GIP
receptor [84]. Being a natural product, it was also considered safe to
administer this molecule to humans. It soon turned out that with a
surplus of the antagonist, it was possible to block in humans most of
the effect of “normal” doses of GIP on insulin secretion [84] and also to
block its actions on adipose tissue blood ﬂow and triglyceride uptake
[85]. The results of antagonism of endogenous GIP are now also being
investigated during mixed meal as well as oral glucose administration.
In these studies [86], the GLP-1 antagonist, exendin 9–39, has also
been given aswell as a combination of GIP 3–30NH2 and Exendin-9-39.
Some representative results are shown in Fig. 5. It is seen, as
expected, that both antagonists led to elevations of the plasma glucose
concentrations in response to the oral glucose administration, and that
the combination resulted in what appears to be an additive effect on
blood glucose. Thus, it could be conﬁrmed that both hormones act to
lower postprandial glucose after a glucose challenge. Looking at insulin
responses, a clear reducing effect was elicited by the GIP antagonist,
whereas exendin 9–39 again inhibited insulin secretion in some indi-
viduals, but increased secretion in others (6 out of 18). Regarding gluca-
gon, exendin 9–39 caused amarked increase in concentrations,whereas
the GIP antagonist, if anything, lowered responses. The combination
resulted in a near neutral response. Thus, it is clear that the effects of
the two hormones on glucagon secretion are opposing. It is also clear
that GIP appears more powerful as an incretin hormone than GLP-1,
the actions of which may be concealed by its strong effect on glucagon
secretion. The combination studies also lend some support to the theory
that the lesser anti-incretin effectiveness of exendin 9–39 as compared
to GIP 3–30NH2 may be related to the effects on glucagon secretion (as
opposed to the theory holding increasing glucose concentrations
responsible), since GIP 3–30NH2 has the opposite effects on glucagon
secretion, but similar or even greater effects on plasma glucose. An esti-
mate of the absolute incretin effect of the two hormones is difﬁcult to
extract from these experiments, since there were no intravenous infu-
sions. The differences in insulin secretion between placebo and double
antagonist experiments seem less than those obtained in experiments
with isoglycemic intravenous and oral glucose challenges, but this com-
parison is invalid, since glucose concentrations are radically changed by
the antagonists. The precise estimate therefore must await intravenous
control studies. In addition, although it was shown that the doses of
both antagonists resulted in major reductions of the effects of the exog-
enous peptides, there is no guarantee that the block of the endogenous
hormones in the combination studies was complete.
Exendin 9–39 has been a great tool for the investigation of the
numerous potential effects of endogenous GLP-1 [87], and apart from
proving the role of GIP as an incretin hormone, it is expected that the
new antagonist will provide a valuable tool for the elucidation of the
many potential extrapancreatic effects of GIP [88]. In addition, the re-
markable effects of the antagonist may point to a therapeutic potential
[88].4. Clinical Importance
As brieﬂy alluded to above, loss of the incretin effect is one of the
fundamental characteristics of T2DM [89]. The loss is thought to partic-
ularly inﬂuence and augment postprandial plasma glucose levels, and it
is due to lack of insulinotropic effect of physiological levels of both GIP
and GLP-1, as clearly demonstrated in infusion studies with physiologi-
cal doses which in healthy individuals would dramatically increase
insulin secretion [90]. Whereas GIP remains inactive regardless of
dose, slightly supraphysiological doses of GLP-1 may stimulate insulin
secretion to levels similar to those observed in healthy individuals in
response to glucose alone [46,91]. One could say that supraphysiological
levels of GLP-1 are able to restore the beta cell's responsiveness to glu-
cose. Why is the beta cell response to the two hormones impaired in
T2DM? This is not known, and it is not known why the two hormones
differ in this respect, but it seems reasonable to assume that the under-
lying mechanism is related to and perhaps identical to that responsible
for the cells' lack of response to glucose (the reason for which is also
unknown!). The deﬁciency develops very early in course of T2DM [19]
and a similar deﬁciency occurs during the development of insulin resis-
tance [92,93]. An improvement may be observed after beta cell rest, as
for instance after optimized glucose control [90]. The ability of larger
doses of GLP-1 to restore beta cell glucose sensitivity is the background
for the development of theGLP-1 receptor agonists for diabetes therapy.5. Conclusion
Using isoglycemic oral and intravenous glucose challenges it can
be demonstrated that up to 3 times more insulin is released during
the oral administration. This is due to the effects of the incretin hor-
mones, GLP-1 and GIP, and from studies with receptor antagonists for
both hormones we now know that lack of both hormones deteriorate
glucose tolerance, apparently with GIP being quantitatively the most
important one in healthy individuals. This contrasts greatly with ﬁnd-
ings in patients with T2DM, in whom the GIP effects is largely lost,
whereas supraphysiological doses of GLP-1 may restore the defective
beta cell response to glucose. The marked glucose-lowering effects of
newly developed GLP-1 RAs support that restoration of the incretin
effect in type 2 DM is one of the most powerful therapeutic approaches
to type two diabetes.Conﬂict-of-Interest
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